Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial

Akira Shimada; Toshiaki Hanafusa; Atsutaka Yasui; Ganghyuck Lee; Yusuke Taneda; Akiko Sarashina; Kosuke Shiki; Jyothis George; Nima Soleymanlou; Jan Marquard

doi:10.1111/dom.13351

Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.13351 ◽

2018 ◽

Vol 20 (9) ◽

pp. 2190-2199 ◽

Cited By ~ 14

Author(s):

Akira Shimada ◽

Toshiaki Hanafusa ◽

Atsutaka Yasui ◽

Ganghyuck Lee ◽

Yusuke Taneda ◽

...

Keyword(s):

Type 1 Diabetes ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Trial

Download Full-text

Faculty Opinions recommendation of Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.740412722.793587361 ◽

2021 ◽

Author(s):

Emily Sims

Keyword(s):

Type 1 Diabetes ◽

Imatinib Therapy ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Recent Onset ◽

Onset Type ◽

Phase 2 Trial

Download Full-text

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(13)70111-6 ◽

2013 ◽

Vol 1 (4) ◽

pp. 284-294 ◽

Cited By ~ 103

Author(s):

Mark R Rigby ◽

Linda A DiMeglio ◽

Marc S Rendell ◽

Eric I Felner ◽

Jean M Dostou ◽

...

Keyword(s):

T Cells ◽

Type 1 Diabetes ◽

Memory T Cells ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Onset Type ◽

Phase 2 Trial ◽

New Onset

Download Full-text

Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(21)00139-x ◽

2021 ◽

Author(s):

Stephen E Gitelman ◽

Brian N Bundy ◽

Ele Ferrannini ◽

Noha Lim ◽

J Lori Blanchfield ◽

...

Keyword(s):

Type 1 Diabetes ◽

Imatinib Therapy ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Recent Onset ◽

Onset Type ◽

Phase 2 Trial

Download Full-text

249-OR: A Randomized, Double-Blind Phase 2 Trial of the CXCR1/2 Inhibitor Ladarixin in Adult Patients with New-Onset Type 1 Diabetes

Diabetes ◽

10.2337/db20-249-or ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 249-OR

Author(s):

EMANUELE BOSI ◽

PAOLO POZZILLI ◽

FRANCESCO GIORGINO ◽

EFISIO COSSU ◽

THOMAS LINN ◽

...

Keyword(s):

Type 1 Diabetes ◽

Adult Patients ◽

Phase 2 ◽

Double Blind ◽

Onset Type ◽

Phase 2 Trial ◽

New Onset

Download Full-text

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(21)00019-x ◽

2021 ◽

Vol 9 (4) ◽

pp. 212-224 ◽

Cited By ~ 3

Author(s):

Matthias von Herrath ◽

Stephen C Bain ◽

Bruce Bode ◽

Jesper Ole Clausen ◽

Ken Coppieters ◽

...

Keyword(s):

Cell Function ◽

Phase 2 ◽

Β Cell ◽

Double Blind ◽

Double Blind Placebo ◽

Recent Onset ◽

Phase 2 Trial ◽

Β Cell Function ◽

Interleukin 21

Download Full-text

A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations

Contemporary Clinical Trials ◽

10.1016/j.cct.2019.105892 ◽

2020 ◽

Vol 90 ◽

pp. 105892 ◽

Cited By ~ 6

Author(s):

Anne T. Reutens ◽

Karin Jandeleit-Dahm ◽

Merlin Thomas ◽

Agus Salim ◽

Alysha M. De Livera ◽

...

Keyword(s):

Type 1 Diabetes ◽

Nadph Oxidase ◽

Urinary Albumin Excretion ◽

Urinary Albumin ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Albumin Excretion ◽

Phase 2 Study

Download Full-text

Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(14)70115-9 ◽

2014 ◽

Vol 2 (9) ◽

pp. 710-718 ◽

Cited By ~ 52

Author(s):

Kurt J Griffin ◽

Paul A Thompson ◽

Michael Gottschalk ◽

Jennifer H Kyllo ◽

Alex Rabinovitch

Keyword(s):

Type 1 Diabetes ◽

Combination Therapy ◽

Phase 2 ◽

Recent Onset ◽

Onset Type ◽

Phase 2 Trial

Download Full-text

Imatinib Therapy for Patients with Recent-Onset Type 1 Diabetes: A Randomised Blinded Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3773520 ◽

2021 ◽

Author(s):

Stephen E. Gitelman ◽

Brian N. Bundy ◽

Ele Ferrannini ◽

Noha Lim ◽

J. Lori Blanchfield ◽

...

Keyword(s):

Type 1 Diabetes ◽

Imatinib Therapy ◽

Phase 2 ◽

Recent Onset ◽

Onset Type ◽

Phase 2 Trial

Download Full-text

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(13)70065-2 ◽

2013 ◽

Vol 1 (4) ◽

pp. 306-316 ◽

Cited By ~ 85

Author(s):

Stephen E Gitelman ◽

Peter A Gottlieb ◽

Mark R Rigby ◽

Eric I Felner ◽

Steven M Willi ◽

...

Keyword(s):

Type 1 Diabetes ◽

Antithymocyte Globulin ◽

Phase 2 ◽

Recent Onset ◽

Onset Type ◽

Phase 2 Trial

Download Full-text

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Yearbook of Paediatric Endocrinology ◽

10.1530/ey.17.14.9 ◽

2020 ◽

Author(s):

Harrison SA ◽

Bashir MR ◽

Guy CD ◽

Zhou R ◽

Moylan CA ◽

...

Keyword(s):

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Alcoholic Steatohepatitis ◽

Phase 2 Trial

Download Full-text